This enduring material takes a deeper dive into one of the four key priorities in the FDA’s Overdose Prevention Framework: encouraging harm reduction. It focuses on the Agency’s vision as it relates to encouraging harm reduction, including expanding availability and access to lifesaving overdose reversal products. The discussion focuses on the impacts of the recent approvals of nonprescription naloxone nasal spray as well as prescription nalmefene nasal spray, another medication for opioid overdose.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 10903 New Hampshire Avenue (HFD-220)
Pricing
100% of listed courses are free
23 of 23 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Addiction Medicine
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- General & Adult Psychiatry
- General Pediatrics
- Hospital Medicine
- Infectious Disease
- Medical Leadership & Administration
- Medical Oncology
- Neurology
- Obstetrics & Gynecology
- Patient Education & Health Literacy
- Patient Safety & Quality Improvement
- Practice Management & Ethics
- Psychopharmacology
- Cross-Specialty
- Infectious Disease
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pediatrics
- Primary care
- Psychiatry
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Podcast / audio
- Credit · Up to 0.5 credits
-
ReleasedJan 16, 2024
-
Last day to claim creditJan 16, 2027 3 months left
-
Food & Drug Administration – Center for Drug Evaluation & Research Q&A with FDA Podcast: A Step Forward in the Treatment of Opioid and Alcohol Dependence with Dr. Iilun Murphy and Dr. Marta Sokolowska
-
Food & Drug Administration – Center for Drug Evaluation & Research FDA Drug Safety Podcast: FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions
-
Food & Drug Administration – Center for Drug Evaluation & Research FDA Drug Safety Podcast: FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use
